Kyungokgo for fatigue in post-COVID 19 survivors: prospective multicenter case series

Korea Institute of Oriental Medicine0 个研究点目标入组 100 人开始时间: 待定最近更新: 2024年5月27日

试验速览

暂无简介。

•Those aged 19 years or older and at least 12 weeks have passed since being diagnosed with COVID-19
•-Those who has continuously experienced fatigue for 4 more than weeks that they did not experience before being diagnosed with COVID-19.
•-Those who scored 36 or more Fatigue Severity Scale (FSS) score.
•-Participants do not have any problems with overall cognitive function and voluntarily agreed to participate in the study through written consent

•-Those with a past or current history of organic diseases that can cause fatigue (cancer, sleep disorders, chronic hepatitis, cirrhosis, chronic renal failure, tuberculosis, asthma, multiple sclerosis)
•-Those with diseases that may affect the taking or absorption of drugs (dysphagia, clinically serious digestive disorders, galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption)
•-Those with uncontrolled diabetes
•-Those with a history of allergy to clinical research drugs (Kyungokgo)
•-Those with a history of liver disease or kidney disease, or if AST, ALT, BUN, and Creatinine exceed three times the upper limit of normal on a blood test.
•-Women who are pregnant, may become pregnant, or are lactating
•-Participating in another study within 30 days prior to participating in a clinical study
•-When the researcher determines that participation in the study is difficult due to clinically significant psychiatric symptoms, medical disease, laboratory findings, etc.

发起方